Hims Hers Health is trading 4.14% down at $29.37, with coverage linking the decline to ongoing class-action legal overhang. - The class action is tied to allegations of deceptive billing and sharing sensitive user health data, following the FTC’s lawsuit. - An investor-law-firm notice appeared October 13; the class action had been reported earlier. - Hers’ Australia launch was announced October 12, but coverage did not link it to the decline. Supplied market readings were mixed, with no substantial market-wide drop.